Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET

Company Participants

Christine Lindenboom - Senior Vice President-Investor Relations and Corporate Communication

Yvonne Greenstreet - Chief Executive Officer

Tolga Tanguler - Chief Commercial Officer

Pushkal Garg - Chief Medical Officer and EVP, Development & Medical Affairs

Jeff Poulton - Chief Financial Officer

Conference Call Participants

Ritu Baral - TD Cowen

Paul Matteis - Stifel

Lisa Munro - RBC

Ellie Merle - UBS

David Lebowitz - Citi

Maury Raycroft - Jefferies

Gena Wang - Barclays

Mike Ulz - Morgan Stanley

Operator

Good day and thank you for standing by. Welcome to the Alnylam Pharmaceuticals Q3 2023 Earnings Conference Call. At this time, participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded.

I would now like to hand the conference call over to the company.

Christine Lindenboom

Good morning. I am Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, our Chief Medical Officer; and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.alnylam.com/events.

During today's call, as outlined on Slide 2, Yvonne will offer some introductory remarks and provide general context, Tolga will provide an update on our global commercial progress, Pushkal will review pipeline update and clinical progress, and Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call to your questions.

I’d like to remind you that today's call will contain remarks concerning Alnylam's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC. In addition, any forward-looking statements represent our views only as to the date of this reporting and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements.

With that, I'd like to turn the call over to Yvonne. Yvonne?